By: Elizabeth Cairns
Novartis plans Phase 3 trial of pacibekitug for CV risk reduction despite Novo Nordisk's failed ZEUS trial of ziltivekimab. Novartis paid $1.4B for drug via Tourmaline Bio.
Elizabeth Cairns is a Senior biopharma journalist at Informa. She covers a wide range of topics within the realms of medicine and healthcare, including pharmaceuticals, health and wellness, healthcare technology, and the intersection of AI and machine learning in the industry. Elizabeth's insights and expertise have been featured in prominent publications such as Citeline and Endpoints News.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Elizabeth Cairns' coverage primarily focuses on the healthcare and pharmaceutical industry, with a strong emphasis on biopharmaceuticals, clinical trials, drug development, and medical research. She frequently cites data and press releases in her articles.
If you are looking to reach out to Elizabeth Cairns for potential coverage or collaboration opportunities, consider offering access to exclusive data or insights related to breakthroughs in drug development or clinical trial results. Given her focus on scientific themes as well as private sector announcements, she might be interested in pitches that provide unique perspectives from key figures within pharmaceutical companies regarding new developments and trends shaping the industry.
This information evolves through artificial intelligence and human feedback. Improve this profile .